Merck & Co., Inc. NYSE: MRK is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the approach can extend beyond tumors with a high number of mutations, a company executive said at the Jefferies Healthcare Conference.
Eliav Barr, Merck’s senior vice president, head of global clinical development and chief medical officer, said the company is entering a data-rich period as it develops medicines for what he described as the “post-KEYTRUDA era.” He pointed to recent phase 3 results and upcoming data from late-stage and proof-of-concept studies.
Cancer vaccine research moves beyond melanoma
Barr said Merck is learning from the INTerpath-001 melanoma study of intismeran autogene, its investigational individualized cancer vaccine. The company is examining which patients responded, how its algorithms might be improved and whether the vaccine could be used without KEYTRUDA or alongside other immune stimulants.
Tumor mutational burden, or TMB, will not be the only factor in determining where the vaccine works, Barr said. He also cited HLA, which plays a role in immune recognition, and the tumor microenvironment.
The kidney cancer study is important because it involves a TMB-low patient population, he said. Results could help researchers understand whether responsiveness to KEYTRUDA, mutation burden or both are important to the vaccine’s performance. Barr said he did not have efficacy data from the kidney study.
He cautioned against overreacting to interim analyses, saying the melanoma results showed little response in the first few months before the effect increased over time. “Science has its own rhythm and timing,” Barr said, adding that repeated doses are intended to prime and boost the immune response.
Merck is also studying the vaccine alone and with BCG in non-muscle invasive bladder cancer. Barr said a vaccine regimen that does not require pembrolizumab, the medicine sold as KEYTRUDA, could be helpful for patients with very early-stage tumors by avoiding exposure to potential autoimmune effects.
Lung cancer combination strategy
Barr also discussed Merck’s plans to develop a PD-L1/VEGF drug alongside sacituzumab for frontline non-small cell lung cancer. He said outside study results and Merck’s own data from China increased the company’s confidence, although the combination still needs testing for potential toxicity.
He described discussions with the U.S. Food and Drug Administration as productive but said the combination’s performance remains to be demonstrated. “Proof is in the pudding,” he said.
Asked about the FDA’s concerns with trials that enroll most patients in China before adding international participants, Barr said the agency wants U.S. patient data that is mature enough to assess consistency with overall results. Merck has moved to front-load U.S. enrollment in its oncology trials, he said.
Targeted treatments for KRAS mutations
For lung cancers driven by KRAS mutations, Barr said he favors potent, narrowly targeted oral drugs that patients can tolerate over broader-acting treatments or chemotherapy when mutation status can be identified.
He said Merck’s investigational G12C drug, calderasib, also known as MK-1084, has shown durable efficacy with pembrolizumab. Merck also has an in-licensed G12D drug, he said.
Barr distinguished pancreatic cancer from lung cancer, saying the disease presents different challenges and that treatments making a survival difference can be important despite their tolerability burden. He said the goal of research is to improve outcomes and tolerability over time.
About Merck & Co., Inc. (NYSE:MRK)
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.